|
| 35576979 | Applying the OMOP Common Data Model to Facilitate Benefit-Risk Assessments of Medicinal Products Using Real-World Data from Singapore and South Korea. | Healthc Inform Res | 2022 |
| 35576979 | Applying the OMOP Common Data Model to Facilitate Benefit-Risk Assessments of Medicinal Products Using Real-World Data from Singapore and South Korea. | Healthc Inform Res | 2022 |
| 32559336 | Prescription patterns of outpatients and the potential of multiplexed pharmacogenomic testing. | Br J Clin Pharmacol | 2021 |
| 33260201 | Towards clinical data-driven eligibility criteria optimization for interventional COVID-19 clinical trials. | J Am Med Inform Assoc | 2021 |
| 33342753 | Renin-angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis. | Lancet Digit Health | 2021 |
| 32559336 | Prescription patterns of outpatients and the potential of multiplexed pharmacogenomic testing. | Br J Clin Pharmacol | 2021 |
| 34763988 | Corrigendum to 'SJS/TEN 2019: From science to translation' [J. Dermatol. Sci. 98/1 (2020) 2-12]. | J Dermatol Sci | 2021 |
| 34763988 | Corrigendum to 'SJS/TEN 2019: From science to translation' [J. Dermatol. Sci. 98/1 (2020) 2-12]. | J Dermatol Sci | 2021 |
| 33342753 | Renin-angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis. | Lancet Digit Health | 2021 |
| 33260201 | Towards clinical data-driven eligibility criteria optimization for interventional COVID-19 clinical trials. | J Am Med Inform Assoc | 2021 |
| 32192826 | SJS/TEN 2019: From science to translation. | J Dermatol Sci | 2020 |
| 32192826 | SJS/TEN 2019: From science to translation. | J Dermatol Sci | 2020 |
| 32180492 | Is HLA-B*58:01 genotyping cost effective in guiding allopurinol use in gout patients with chronic kidney disease? | Pharmacogenomics | 2020 |
| 32457602 | Usage Pattern of Carbamazepine and Associated Severe Cutaneous Adverse Reactions in Singapore Following Implementation of <i>HLA-B*15:02</i> Genotyping as Standard-of-Care. | Front Pharmacol | 2020 |
| 32587982 | Renin-angiotensin system blockers and susceptibility to COVID-19: a multinational open science cohort study. | medRxiv | 2020 |
| 32844466 | Comparison of laboratory threshold criteria in drug-induced liver injury detection algorithms for use in pharmacovigilance. | Pharmacoepidemiol Drug Saf | 2020 |
| 32844466 | Comparison of laboratory threshold criteria in drug-induced liver injury detection algorithms for use in pharmacovigilance. | Pharmacoepidemiol Drug Saf | 2020 |
| 32587982 | Renin-angiotensin system blockers and susceptibility to COVID-19: a multinational open science cohort study. | medRxiv | 2020 |
| 32180492 | Is HLA-B*58:01 genotyping cost effective in guiding allopurinol use in gout patients with chronic kidney disease? | Pharmacogenomics | 2020 |
| 32457602 | Usage Pattern of Carbamazepine and Associated Severe Cutaneous Adverse Reactions in Singapore Following Implementation of <i>HLA-B*15:02</i> Genotyping as Standard-of-Care. | Front Pharmacol | 2020 |
| 31160013 | Detecting adverse drug reactions in discharge summaries of electronic medical records using Readpeer. | Int J Med Inform | 2019 |
| 31933229 | Ethnicity-Specific Drug Safety Data in European Medicines Agency Registration Dossiers, European Public Assessment Reports, and European and Singapore Drug Labels: Lost in Translation? | Pharmaceut Med | 2019 |
| 30250149 | Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adults. | Pharmacogenomics J | 2019 |
| 31160013 | Detecting adverse drug reactions in discharge summaries of electronic medical records using Readpeer. | Int J Med Inform | 2019 |
| 31933229 | Ethnicity-Specific Drug Safety Data in European Medicines Agency Registration Dossiers, European Public Assessment Reports, and European and Singapore Drug Labels: Lost in Translation? | Pharmaceut Med | 2019 |
| 30250149 | Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adults. | Pharmacogenomics J | 2019 |
| 29105735 | Research Directions in Genetic Predispositions to Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis. | Clin Pharmacol Ther | 2018 |
| 29310768 | SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. | J Allergy Clin Immunol Pract | 2018 |
| 29108136 | Application and optimisation of the Comparison on Extreme Laboratory Tests (CERT) algorithm for detection of adverse drug reactions: Transferability across national boundaries. | Pharmacoepidemiol Drug Saf | 2018 |
| 29105735 | Research Directions in Genetic Predispositions to Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis. | Clin Pharmacol Ther | 2018 |
| 29310768 | SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. | J Allergy Clin Immunol Pract | 2018 |
| 29108136 | Application and optimisation of the Comparison on Extreme Laboratory Tests (CERT) algorithm for detection of adverse drug reactions: Transferability across national boundaries. | Pharmacoepidemiol Drug Saf | 2018 |
| 27706800 | Development and validation of algorithms for the detection of statin myopathy signals from electronic medical records. | Clin Pharmacol Ther | 2017 |
| 28594314 | Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach. | Pharmacogenomics | 2017 |
| 28852525 | Real world experience with pegylated interferon and ribavirin in hepatitis C genotype 1 population with favourable <i>IL28B</i> polymorphism. | Gastroenterol Rep (Oxf) | 2017 |
| 27706800 | Development and validation of algorithms for the detection of statin myopathy signals from electronic medical records. | Clin Pharmacol Ther | 2017 |
| 28594314 | Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach. | Pharmacogenomics | 2017 |
| 28852525 | Real world experience with pegylated interferon and ribavirin in hepatitis C genotype 1 population with favourable <i>IL28B</i> polymorphism. | Gastroenterol Rep (Oxf) | 2017 |
| 27509020 | Extended Evaluation of Virological, Immunological and Pharmacokinetic Endpoints of CELADEN: A Randomized, Placebo-Controlled Trial of Celgosivir in Dengue Fever Patients. | PLoS Negl Trop Dis | 2016 |
| 27509020 | Extended Evaluation of Virological, Immunological and Pharmacokinetic Endpoints of CELADEN: A Randomized, Placebo-Controlled Trial of Celgosivir in Dengue Fever Patients. | PLoS Negl Trop Dis | 2016 |
| 25461248 | Reducing hypersensitivity reactions with HLA-B*5701 genotyping before abacavir prescription: clinically useful but is it cost-effective in Singapore? | Pharmacogenet Genomics | 2015 |
| 25461248 | Reducing hypersensitivity reactions with HLA-B*5701 genotyping before abacavir prescription: clinically useful but is it cost-effective in Singapore? | Pharmacogenet Genomics | 2015 |
| 26554739 | Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore. | Pharmacogenomics | 2015 |
| 26554739 | Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore. | Pharmacogenomics | 2015 |
| 24394201 | Building pharmacogenetics into a pharmacovigilance program in Singapore: using serious skin rash as a pilot study. | Pharmacogenomics J | 2014 |
| 24394201 | Building pharmacogenetics into a pharmacovigilance program in Singapore: using serious skin rash as a pilot study. | Pharmacogenomics J | 2014 |
| 24861855 | Pharmacogenomic diversity in Singaporean populations and Europeans. | Pharmacogenomics J | 2014 |
| 24877997 | Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial. | Lancet Infect Dis | 2014 |
| 24861855 | Pharmacogenomic diversity in Singaporean populations and Europeans. | Pharmacogenomics J | 2014 |
| 24877997 | Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial. | Lancet Infect Dis | 2014 |